Shift Health was engaged by a leading US investment firm to evaluate an asset and project sales in order to inform their decision to invest in an established biotechnology company expanding into new markets.
A multinational pharmaceutical company sought support to engage with haemophilia A individuals and caregivers to gather firsthand perspectives on the impact of current and value of future therapies.
MaRS Innovation (now called Toronto Innovation Acceleration Partners – TIAP) sought to develop a novel approach to investing in research breakthroughs and bringing them to market.